Stay updated on Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.
Latest updates to the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.SummaryDifference0.1%
- Check22 days agoChange DetectedThe website has been updated to version v2.11.0, now displaying 'Results Submitted', while the previous version v2.10.5 has been removed along with the notice about delays in study record information.SummaryDifference0.8%
- Check30 days agoChange DetectedClinicalTrials.gov is addressing delays in displaying study record information, and the site has been updated to version 2.10.5, replacing the previous version 2.10.3.SummaryDifference0.7%
- Check44 days agoChange DetectedThe website has been updated from version v2.10.2 to v2.10.3.SummaryDifference0.1%
- Check65 days agoChange DetectedThe website has been updated from version 2.10.0 to 2.10.2, indicating new features or improvements.SummaryDifference0.1%
- Check87 days agoChange DetectedThe study has been updated to version v2.10.0 and now includes 11 locations, replacing the previous version v2.9.7.SummaryDifference0.3%
Stay in the know with updates to Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.